XML 43 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Financial Instruments and Fair Value Measurements (Tables)
 9 Months Ended
Sep. 24, 2021
Fair Value Disclosures [Abstract]  
Schedule of Fair Value of Assets and Liabilities Measured on a Recurring Basis
The following tables provide a summary of the significant assets and liabilities that are measured at fair value on a recurring basis at the end of each period:

September 24,
2021
Quoted Prices in Active Markets for Identical Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Assets:
Debt and equity securities held in rabbi trusts
$37.9 $23.7 $14.2 $— 
Equity securities
37.3 37.3 — — 
$75.2 $61.0 $14.2 $— 
Liabilities:
Deferred compensation liabilities
$35.9 $— $35.9 $— 
Contingent consideration and acquired contingent liabilities
27.1 — — 27.1 

$63.0 $— $35.9 $27.1 
December 25,
2020
Quoted Prices in Active Markets for Identical Assets
(Level 1)
Significant Other Observable Inputs
(Level 2)
Significant Unobservable Inputs
(Level 3)
Assets:
Debt and equity securities held in rabbi trusts$33.0 $23.5 $9.5 $— 
Equity securities31.1 31.1 — — 
$64.1 $54.6 $9.5 $— 
Liabilities:
Deferred compensation liabilities$38.0 $— $38.0 $— 
Contingent consideration and acquired contingent liabilities34.7 — — 34.7 
$72.7 $— $38.0 $34.7 
Schedule of Reconciliation of Changes in Fair Value of Contingent Liabilities The following table summarizes the activity for contingent consideration:
Balance as of December 25, 2020$34.7 
Fair value adjustments
(7.6)
Balance as of September 24, 2021$27.1 
Schedule of Carrying Amount and Fair Value of Long-term Debt The following table presents the carrying values and estimated fair values of the Company's debt as of the end of each period:
September 24, 2021December 25, 2020
Carrying
Value		Fair
Value		Carrying
Value		Fair
Value
Level 1:
5.75% senior notes due August 2022$610.3 $353.1 $610.3 $191.2 
4.75% senior notes due April 2023133.7 49.7 133.7 11.1 
5.625% senior notes due October 2023514.7 302.9 514.7 158.9 
5.50% senior notes due April 2025387.2 226.9 387.2 115.4 
10.00% first lien senior notes due April 2025495.0 539.5 495.0 528.4 
10.00% second lien senior notes due April 2025322.9 322.1 322.9 279.0 
Revolving credit facility900.0 900.0 900.0 900.0 
Level 2:
9.50% debentures due May 202210.4 7.7 10.4 4.2 
8.00% debentures due March 20234.4 3.2 4.4 1.3 
Term loan due September 20241,403.9 1,351.5 1,505.2 1,386.9 
Term loan due February 2025372.6 357.7 399.5 367.9 
Total Debt$5,155.1 $4,414.3 $5,283.3 $3,944.3 
Schedules of Concentration of Risk
The following table shows net sales attributable to distributors that accounted for 10.0% or more of the Company's total segment net sales. which excludes the one-time charge incurred during the three and nine months ended September 25, 2020 related to the Medicaid lawsuit:
Three Months EndedNine Months Ended
September 24,
2021		September 25,
2020		September 24,
2021		September 25,
2020
CuraScript, Inc.
27.0 %28.1 %25.2 %27.7 %

The following table shows accounts receivable attributable to distributors that accounted for 10.0% or more of the Company's gross accounts receivable at the end of each period:
September 24,
2021		December 25,
2020
AmerisourceBergen Corporation
37.1 %33.6 %
McKesson Corporation
16.2 18.2 

The following table shows net sales attributable to products that accounted for 10.0% or more of the Company's total segment net sales, which excludes the one-time charge incurred during the three and nine months ended September 25, 2020 related to the Medicaid lawsuit:
Three Months EndedNine Months Ended
September 24,
2021		September 25,
2020		September 24,
2021		September 25,
2020
Acthar Gel28.3 %27.9 %26.3 %27.9 %
INOmax19.4 20.3 21.0 21.2 
Ofirmev*12.7 *10.5 
Therakos12.3 *12.3 *
*Net sales attributable to these products were less than 10.0% of total net sales during the respective periods presented above.